It is good news for some breast cancer patients with the announcement that two new drugs have been made available on the NHS.
The National Institute for Health and Care Excellence (NICE) has approved the drugs Alpelisib and Trodelvy.
Alpelisib is a targeted treatment for a certain type of advanced breast cancer (ER positive/HER2 negative) in patients with a specific PIK3CA gene mutation. It is used after disease has progressed on endocrine treatment.
Trodelvy can benefit women with triple negative incurable secondary breast cancer who have already received at least two previous treatments. It is already available on a case-by-case basis to a limited number of patients at The Clatterbridge Cancer Centre.
We are working to offer these drugs to patients who could benefit as quickly as we can. Our specialist breast cancer oncologists will discuss the situation with eligible patients as soon as the treatment is available here.
Both the drugs are to be made available by the NHS in England through the Cancer Drugs Fund.